UBS Group’s Codiak BioSciences, Inc. Common Stock CDAK Stock Holding History

UBS Group’s Portfolio CDAK Stock Details CDAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-91	Closed	-$16	–	10400
2023 Q1	$16	Hold	91	–	–	﹤0.01%	9440
2022 Q4	$36	Sell	91 -159	-64%	-$105	﹤0.01%	10513
2022 Q3	$0	Sell	250 -366	-59%	-$768	﹤0.01%	11435
2022 Q2	$2K	Buy	+616	New	+$2.16K	﹤0.01%	9726
2022 Q1	–	Sell	-3,722	Closed	-$41K	–	11299
2021 Q4	$41K	Sell	3,722 -1,878	-34%	-$26K	﹤0.01%	7103
2021 Q3	$91K	Sell	5,600 -1,900	-25%	-$34K	﹤0.01%	5898
2021 Q2	$139K	Sell	7,500 -252	-3%	-$4.84K	﹤0.01%	5624
2021 Q1	$116K	Sell	7,752 -831	-10%	-$18.1K	﹤0.01%	5855
2020 Q4	$278K	Buy	+8,583	New	+$114K	﹤0.01%	5025

UBS Group's CDAK Position: Q2 2023 in Review

UBS Group sold out of Codiak BioSciences, Inc. Common Stock (CDAK) in Q2 2023, closing a stake of 91 shares — an estimated $16 sold.

UBS Group first reported a position in CDAK in Q4 2020 and held it in 9 quarters. The position peaked at $278K in Q4 2020. 1 fund tracked by Wall St. Rank holds CDAK as of Q2 2023.

UBS Group reported no remaining Codiak BioSciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
UBS Group sold 91 Codiak BioSciences, Inc. Common Stock shares in Q2 2023, an estimated $16.
UBS Group first reported a position in Codiak BioSciences, Inc. Common Stock in Q4 2020 and held it in 9 quarters.
UBS Group's Codiak BioSciences, Inc. Common Stock position peaked at $278K in Q4 2020.
1 fund tracked by Wall St. Rank held Codiak BioSciences, Inc. Common Stock as of Q2 2023.

Based on UBS Group's 13F filing for Q2 2023, filed 11 Aug 2023.